Drug profile · INN
romosozumab-aqqg
EVENITY
romosozumab-aqqg (EVENITY) is a sclerostin inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — romosozumab-aqqg
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
romosozumab-aqqg (EVENITY) is a sclerostin inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Sclerostin inhibitor
Primary target: Sclerostin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is romosozumab-aqqg?
romosozumab-aqqg (EVENITY) is a sclerostin inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for romosozumab-aqqg?
EVENITY is a marketed brand name for romosozumab-aqqg. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of romosozumab-aqqg?
romosozumab-aqqg has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.